25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials

Authors :: Melinda Gooderham
Eva Cullen
Luke Peterson
Diamant Thaçi
Peter Foley
Richard B. Warren
April W. Armstrong
Cynthia Madden
Bruce Strober
Christopher Cioffi
Source :: Journal of the American Academy of Dermatology. 85:AB76
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Moderate to severe
Plaque psoriasis
medicine.medical_specialty
business.industry
Double blinded
Internal medicine
Bimekizumab
Patient subgroups
Medicine
Dermatology
business

Full Text Access

Tools